US 12,378,319 B2
Anti-CD137 molecules and use thereof
Peter Peizhi Luo, Suzhou (CN); Fangyong Du, Suzhou (CN); Yan Li, Suzhou (CN); Guizhong Liu, Suzhou (CN); Jun Chen, Suzhou (CN); Xiaohong She, Suzhou (CN); and Peter Cheung, Suzhou (CN)
Assigned to Adagene Inc., Grand Cayman (KY)
Filed by Adagene Inc., Grand Cayman (KY)
Filed on Dec. 28, 2021, as Appl. No. 17/564,022.
Application 17/564,022 is a division of application No. 16/108,018, filed on Aug. 21, 2018, granted, now 11,242,395.
Application 16/108,018 is a continuation in part of application No. PCT/CN2017/098332, filed on Aug. 21, 2017.
Prior Publication US 2022/0204637 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/001102 (2018.08); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. A polynucleotide encoding an antibody, or antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof binds to an extracellular domain of human CD137, and comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises an HVR-H1, an HVR-H2, and an HVR-H3, the light chain variable region comprises an HVR-L1, an HVR-L2, and an HVR-L3, and wherein:
(1) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 731, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 755, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 779, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 803, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 827, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 851;
(2) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 711, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 735, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 759, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 783, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 807, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 831; or
(3) the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 712, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 736, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 760, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 784, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 808, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 832.